Cataract News and Research

Latest Cataract News and Research

FDA clears OptiMedica's Catalys Precision Laser System

Global ophthalmic company OptiMedica Corp. has announced the U.S. Food and Drug Administration (FDA) 510(k) market clearance of its Catalys Precision Laser System, a next generation laser cataract surgery system that brings unequaled precision and accuracy and a markedly streamlined workflow to the laser cataract procedure.

22 Dec 2011

FDA, other organizations unveil program to monitor cataract surgery devices

The U.S. Food and Drug Administration and other government and professional organizations today unveiled a program to monitor medical devices used in cataract surgery in an effort to stem outbreaks of a rare, inflammatory condition associated with the procedure.

21 Dec 2011

Herzig Eye Institute named TearScience's first Center of Excellence

TearScience, Inc., a privately-held medical device company, today announced Toronto-based Herzig Eye Institute, one of the leading authorities in laser vision correction and advanced cataract and refractive surgery, as its first Center of Excellence.

5 Dec 2011

Japan approves Visian Toric Implantable Collamer Lens

STAAR Surgical Company, the leading developer, manufacturer and marketer of minimally invasive refractive lenses, today announced that its Visian Toric Implantable Collamer Lens has been approved by the Japanese Ministry of Health, Labor and Welfare.

29 Nov 2011

Bayer, Regeneron commence EYLEA Phase 3 clinical trial for wet AMD in China

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that they have initiated a Phase 3 clinical trial evaluating the efficacy and safety of EYLEA (aflibercept) Injection in the neovascular form of age-related macular degeneration (wet AMD) in China.

28 Nov 2011

FDA approves EYLEA for treatment of wet Age-related Macular Degeneration

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD) at a recommended dose of 2 milligrams every four weeks for the first 12 weeks, followed by 2 mg every eight weeks.

19 Nov 2011

Regeneron receives FDA approval for Eylea to treat wet AMD

The U.S. Food and Drug Administration today approved Eylea (aflibercept) to treat patients with wet (neovascular) age-related macular degeneration (AMD), a leading cause of vision loss and blindness in Americans ages 60 and older.

18 Nov 2011

STAAR Surgical's nanoFLEX Toric Collamer Single Piece IOL receives CE Mark approval

STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced it has received CE Mark approval for its nanoFLEX Toric Collamer Single Piece IOL.

16 Nov 2011

Omeros third quarter net loss decreases to $6.5 million

Omeros Corporation, a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the third quarter of 2011.

9 Nov 2011

Mouse anti-aging study generates expert commentary

Age related changes like wrinkles, muscle wasting and cataracts could be delayed in mice, say researchers in the US. They achieved the feat by removing old cells that had stopped dividing. These accumulate naturally with age. The scientists believe their findings could eventually “really have an impact” in the care of the elderly. Experts said the results were “fascinating”, but should be taken with a bit of caution.

6 Nov 2011

Carl Zeiss Meditec to showcase new clinical and productivity tools at AAO annual meeting

Carl Zeiss Meditec will showcase new clinical and productivity tools across the glaucoma, retina, cataract and refractive workplaces during this week's American Academy of Ophthalmology Annual Meeting in Orlando at booth #821.

24 Oct 2011

Femtosecond laser cataract surgery safe and effective than standard procedure

Two new studies add to the growing body of evidence that a new approach to cataract surgery may be safer and more efficient than today's standard procedure. The new approach, using a special femtosecond laser, is FDA-approved, but not yet widely available in the United States. It's one of the hottest topics this week at the 115th Annual Meeting of the American Academy of Ophthalmology.

24 Oct 2011

CWRU to lead Cornea Preservation Time Study

Researchers at Case Western Reserve University School of Medicine will lead a national study determining if corneas transplanted up to two weeks after donor death work as well as corneas transplanted up to one week after donor death. The National Eye Institute has awarded a $12.3 million grant to support the work.

20 Oct 2011

Omeros initiates OMS302 Phase 3 trial in intra-ocular lens replacement surgery

Omeros Corporation today announced that the first patients have been treated in the Company's Phase 3 clinical program evaluating OMS302 in intra-ocular lens replacement surgery.

11 Oct 2011

Increased competition in the NHS has not harmed deprived neighbourhoods: Study

Increased competition in the NHS has not harmed deprived neighbourhoods, according to new research from the Centre for Health Economics (CHE), University of York.

10 Oct 2011

STAAR's new Visian ICL with CentraFLOW technology showcased at ESCRS congress

STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced the Visian Implantable Collamer Lens (ICL), and new Visian ICL with CentraFLOW technology utilizing the KS-AquaPORT, were featured prominently in twice as many presentations at the 2011 Congress of European Society of Cataract and Refractive Surgeons (ESCRS) as those on the ICL during last year's Congress.

23 Sep 2011

IRIDEX licenses rights to Ocunetics' intellectual property

IRIDEX Corporation today announced that it has exclusively licensed the rights to all of the intellectual property of Ocunetics, Inc., a privately held company based in Alamo, California. Ocunetics develops procedure-enabling medical devices that are intended to increase surgeons' efficiency, while improving case predictability for ophthalmic surgeries.

21 Sep 2011

Amgen's Prolia receives FDA approval for new indications to treat cancer patients

Amgen today announced that the U.S. Food and Drug Administration (FDA) approved two new indications for Prolia® (denosumab) as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer and as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer.

19 Sep 2011

Topcon Europe Medical to distribute LensAR product line in Europe

Topcon Europe Medical BV and LensAR Inc announce their intent to enter into a long term strategic cooperation. Topcon Europe Medical BV will be responsible for the distribution and marketing the LensAR product line in Europe.

17 Sep 2011